Cancer

Title
Comparing Standard Endocrine Therapy and Chemotherapy in Women with Hormone-responsive Breast Cancer
Trial Number
203428031611
Number of Participants
4,000
Principal Investigator

Kathy S. Albain

M.D.
Hematology/Oncology
Professor
Eligibility

Patients ages > 18 years old with the following criteria may be eligible: must have a histologically confirmed diagnosis of node-positive (one to three nodes) invasive breast carcinoma with positive estrogen and/or progesterone receptor status and negative HER-2, as determined by IHC or non-amplified FISH for screening; have undergone axillary staging by sentinel node biopsy or axillary lymph node dissection (ALND). Additional requirements are in the protocol.

Purpose

The purpose of this study is to find out if the recurrence score can help decide whether participants should receive chemotherapy or not.

Enrollment

(708) 327-3102

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.